title: BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.
authors.forename: M
authors.initials: M
authors.lastname: Abe
authors.forename: S
authors.initials: S
authors.lastname: Kido
authors.forename: M
authors.initials: M
authors.lastname: Hiasa
authors.forename: A
authors.initials: A
authors.lastname: Nakano
authors.forename: A
authors.initials: A
authors.lastname: Oda
authors.forename: H
authors.initials: H
authors.lastname: Amou
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D053264:B-Cell Activating Factor / Q000502:physiology*; D002470:Cell Survival / Q000502:physiology; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D010010:Osteoclasts / Q000502:physiology; D053303:Transmembrane Activator and CAML Interactor Protein / Q000235:genetics / Q000627:therapeutic use*; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000502:physiology*
chemical_list: D053264:B-Cell Activating Factor; D007141:Immunoglobulin Fc Fragments; C505719:TNFSF13B protein, human; D053303:Transmembrane Activator and CAML Interactor Protein; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13